Advanced Hodgkin’s Disease: ABVD Is Better, Yet Is Not Good Enough!
- 15 February 2003
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (4) , 583-585
- https://doi.org/10.1200/jco.2003.11.072
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional Therapy for Patients With Advanced Hodgkin’s Lymphoma Responding to Front-Line TherapyJournal of Clinical Oncology, 2003
- Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin’s Disease: Report of an Intergroup TrialJournal of Clinical Oncology, 2003
- Long-Term Follow-up of Hodgkin's Disease TrialNew England Journal of Medicine, 2002
- ABVD versus Stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trialAnnals of Oncology, 2002
- Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignanciesBone Marrow Transplantation, 2000
- Cellular Origin of Human B-Cell LymphomasNew England Journal of Medicine, 1999
- A Prognostic Score for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 1998
- Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidinesAnnals of Oncology, 1996
- Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVDNew England Journal of Medicine, 1992
- Testicular dysfunction in Hodgkin's disease before and after treatmentEuropean Journal of Cancer and Clinical Oncology, 1991